Skip to content

DTaP/IPV/Hib/HepB (6 in 1) vaccine - 6 in 1 vaccine information for health professionals

Some of the links included in this information lead to content created by other organisations and may not be available in Welsh. 

Diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, Hib (Haemophilus influenzae type b) and hepatitis B are notifiable diseases. 

The 6-in-1 vaccine protects against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, Hib (Haemophilus influenzae type b) and hepatitis B and was introduced for all UK babies born on, or after 1st August 2017. 

The first three doses of Hib-containing vaccine are administered at 8, 12, and 16 weeks with the 6-in-1 (DTaP/IPV/Hib/HepB) vaccine.  

Changes to the childhood immunisation schedule for Wales and impact on the 6-in-1 vaccine  

Menitorix© (Hib/MenC) was discontinued on 30 June 2025. Menitorix© was the fourth Hib vaccine dose in the routine schedule. 

As a result of the cessation of Menitorix©, the Joint Committee on Vaccination and Immunisation (JCVI) who advise the UK government on vaccination matters, recommended changes to the childhood immunisation schedule for Wales.  

The JCVI recommendations, include: 

 From 1 January 2026 

  • An additional dose of Hib-containing multivalent vaccine (DTaP/IPV/Hib/HepB) given at 18 months of age. This is to replace the Hib previously given at 12 months (Hib/MenC).  
  • The 18-month visit is a new appointment on the UK childhood immunisation schedule. 

For more information about changes to the childhood immunisation schedule, including frequently asked questions, visit: 

About the vaccine 

The 6-in-1 vaccine is marketed for use in the UK under the brand names Infarix hexa® and Vaxelis®. 

Infanrix hexa® is an inactivated vaccine in a powder and suspension for reconstitution before injection. Vaxelis® is an inactivated injectable vaccine in a pre-filled syringe presentation. 

Guidance on the treatment of tetanus cases and management of tetanus prone wounds can be is available at: 

Summary of product characteristics

More information about the vaccine can be found in the Green Book chapters for each disease. See clinical resources and information section. 

Guidance in the Green Book supersedes the Summary of product characteristics (SmPC).  

Reporting side effects 

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. You should report suspected adverse reactions of vaccines and medicines online at the Yellow Card website (external site), by downloading the Yellow Card app, or by calling 0800 731 6789 (Monday to Friday, 9am to 5pm). 

The complete routine immunisation schedule includes information about routine and non-routine vaccinations.

Guidance

Vaccination programme recommendations from the Joint Committee on Vaccination and Immunisation (JCVI) and Welsh Government policy can be found at the links below.

Joint Committee on Vaccination and Immunisation on the UK Government website (external site) – read JCVI publications and statements; search e.g. polio.

Guidance on changes to the childhood immunisation schedule in Wales (external site) can be found on the UK Government website. 

The complete routine immunisation schedule for Wales is available on our website and includes information about routine and non-routine vaccinations. 

Policy and guidance can also be found on the Public Health Wales policy, letters and Welsh Government SharePoint page (access for NHS healthcare staff). 

Clinical resources and information

Patient group directions (PGDs) and protocols

PGD templates for vaccines can be found on the patient group directions (PGDs) and protocols page (external site).

Further clinical resources and information

More information 

Data and surveillance

Vaccination surveillance information can be found on the pages below:

Page last reviewed: 25th March 2026